Posted 9/11/2019 6:36 AM (GMT -6)
Recent studies have shown that methylene blue can be a highly effective treatment against bartonella henselae. What opinion do you have about this? I have bought mitoblue from a good lab to test myself... it's a relative nontoxic "drug" with good absorbption and tissue distribution.
Abstract:Bartonella henselae can cause various infections in humans, ranging from benign andself-limiting diseases to severe and life-threatening diseases as well as persistent infections that arediﬃcult to treat. To develop more eﬀective treatments for persistent Bartonella infections, in thisstudy, we performed a high-throughput screen of an FDA-approved drug library against stationaryphase B. henselae using the SYBR Green I/propidium iodide (PI) viability assay. We identiﬁed 110 drugcandidates that had better activity against stationary phase B. henselae than ciproﬂoxacin, and amongthe top 52 drug candidates tested, 41 drugs were conﬁrmed by microscopy to have higher activity thanthe current frontline antibiotic erythromycin. The identiﬁed top drug candidates include pyrviniumpamoate, daptomycin, methylene blue, azole drugs (clotrimazole, miconazole, sulconazole, econazole,oxiconazole, butoconazole, bifonazole), aminoglycosides (gentamicin and streptomycin, amikacin,kanamycin), amifostine (Ethyol), antiviral Lopinavir/ritonavir, colistin, nitroxoline, nitrofurantoin,verteporﬁn, pentamidine, berberine, aprepitant, olsalazine, clinaﬂoxacin, and clofoctol. Pyrviniumpamoate, daptomycin, methylene blue, clotrimazole, and gentamicin and streptomycin at theirrespective maximum drug concentration in serum (Cmax) had the capacity to completely eradicatestationary phase B. henselae after 3-day drug exposure in subculture studies. While the currentlyused drugs for treating bartonellosis, including rifampin, erythromycin, azithromycin, doxycycline,and ciproﬂoxacin, had very low minimal inhibitory concentration (MIC) against growing B. henselae,they had relatively poor activity against stationary phase B. henselae, except aminoglycosides.The identiﬁed FDA-approved agents with activity against stationary phase B. henselae should facilitatedevelopment of more eﬀective treatments for persistent Bartonella infections.